https://www.reuters.com/business/healthcare-pharmaceuticals/us-obesity-docs-expect-lilly-weight-loss-drug-show-similar-heart-benefit-wegovy-2023-12-01/
Some leading U.S. obesity specialists say they expect Eli Lilly’s <a href="https://www.reuters.com/markets/companies/LLY.N" target="_blank">(LLY.N)</a> powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s <a hre…
Create an account
or login to join the discussion